
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is positioning itself well within the competitive market of injectable neurotoxins and HA gels, with key advantages such as the only HA gel with a weight loss mention in its label and potential expansion into biostimulators and hair procedures. Additionally, the company has a strong commercial infrastructure and capital structure to support future growth. With a stable neurotoxin market and increasing interest in aesthetic treatments for volume loss, Evolus is poised for continued success and potential market share gains in the future.
Bears say
Evolus is currently performing well in the medical aesthetics market with their two commercially available products, Jeuveau and Evolysse, contributing positively to their YoY revenue growth. However, their high operating expenses and risks such as potential supply chain challenges and slower-than-expected ramp of Evolysse could hinder their future financial success. Their current valuation may be attractive, but their outlook may be impacted by a deteriorating consumer spending environment and competition in the market.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares